Unsealed 188Rhenium Resin Brachytherapy in Non-Surgical Candidates With Refractory Basal Cell Carcinoma: Clinical Outcomes
Keywords:
Basal Cell Carcinoma, High-Dose Brachytherapy, 188rhenium, Non-Surgical Candidates, Refractory Skin CancerAbstract
Introduction: High-dose brachytherapy using a non-sealed 188Rhenium resin (188Re) is a new treatment option for difficult-to-treat basal cell carcinoma (BCC), that ensures a radical oncological outcome minimizing side effects.
Objectives: The aim of this retrospective study is to evaluate the clinical efficacy of high-dose standardized brachytherapy using an unsealed 188Re in the management of difficult-to-treat BCCs and to evaluate the risk factors of relapses.
Methods: Between October 2017 and December 2022, patients affected by difficult-to-treat BCC were selected. Inclusion criteria: histologically proven cutaneous BCC; thickness invasion not deeper than 3 mm; lesion located in the scalp, face, ears, or fingers or other areas in which surgery would have been difficult to perform or to destroy with scarce cosmetic-functional result; and contraindication or refusal of surgery. All patients performed follow-up visits with videodermoscopy every 4-6 months.
Results: Sixty-four consecutive patients, affected by 82 histologically proven high-risk BCCs, were enrolled: 60 were nodular, 9 sclerodermiform, and 13 superficial. Average follow-up was 24 months. Brachytherapy with 188Re healed 93% of difficult-to-treat BCCs with an average time to relapse of 24 months. No statistically significant differences in response to brachytherapy were found in the anatomical area treated, size of the tumor, or previously treated vs. naive BCCs. The sclerodermiform histotype has a 7-fold higher risk of recurrence than nodular histotype; recurrence occurring approximately 12 weeks earlier.
Conclusion: High-dose 188Re brachytherapy is a noninvasive, easy to perform, and tolerable approach to treat difficult BCC when surgery or other therapy techniques are not feasible.
References
Garcovich S, Colloca G, Sollena P et al. Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology. Aging Dis. 2017; 8 (5): 643-661. DOI: 10.14336/AD.2017.0503. PMID: 28966807
American Cancer Society Cancer Statistics 2021 Report. J Nucl Med. 2021; 62 (3): 12N. PMID: 33622967
Lubeek SF, van Vugt LJ, Aben KK, van de Kerkhof PC, Gerritsen MP. The Epidemiology and Clinicopathological Features of Basal Cell Carcinoma in Patients 80 Years and Older: A Systematic Review. JAMA Dermatol. 2017;153 (1): 71-78. DOI: 10.1001/jamadermatol.2016.3628. PMID: 27732698
Schmults CD, Blitzblau R, Aasi SZ, et al. Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023; 21 (11): 1181-1203. DOI: 10.6004/jnccn.2023.0056. PMID: 37935106
Hernandez LE, Mohsin N, Levin N, Dreyfuss I, Frech F, Nouri K. Basal cell carcinoma: An updated review of pathogenesis and treatment options. Dermatol Ther. 2022; 35 (6): e15501. DOI: 10.1111/dth.15501. PMID: 35393669
Grob JJ, Guminski A, Malvehy J et al. Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition. J Eur Acad Dermatol Venereol. 2021; 35 (10): 1949-1956. DOI: 10.1111/jdv.17466. PMID: 34432327
Peris K, Fargnoli MC, Kaufmann R et al. EADO”A, EDF”B, ESTRO”C, UEMS”D and EADV”E. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. Eur J Cancer. 2023;192:113254. DOI: 10.1016/j.ejca.2023.113254. PMID: 37604067
Lancellotta V, Kovács G, Tagliaferri L et al. The role of personalized Interventional Radiotherapy (brachytherapy) in the management of older patients with non-melanoma skin cancer. J Geriatr Oncol. 2019; 10 (3): 514-517. doi: 10.1016/j.jgo.2018.09.009. PMID: 30314955
Cipriani C, Desantis M, Dahlhoff Get al. Personalized irradiation therapy for NMSC by rhenium-188 skin cancer therapy: a long-term retrospective study. J Dermatolog Treat. 2022; 33 (2): 969-975. DOI: 10.1080/09546634.2020.1793890. PMID: 32648530
Sedda AF, Rossi G, Carrozzo AM et al. Superficial brachytherapy with beta emitting isotopes for the treatment of basal cell carcinoma. J Invest Dermatol. 2006; 126: S37. EADO Conjoint Symposium on Melanoma Therapy
Sedda AF, Rossi G, Cipriani C, Carrozzo AM, Donati P. Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma. Clin Exp Dermatol. 2008; 33 (6): 745–749. DOI: 10.1111/j.1365-2230.2008.02852.x. PMID: 18681873
Doggett SW, Willoughby M, Miller KA, Mafong E. Long-term clinical outcomes of non-melanoma skin cancer patients treated with electronic brachytherapy. J Contemp Brachytherapy. 2023; 15 (1): 9-14. DOI: 10.5114/jcb.2023.125580. PMID: 3697043
Castellucci P, Savoia F, Farina A, et al. High dose brachytherapy with non sealed 188Re (rhenium) resin in patients with non-melanoma skin cancers (NMSCs): single center preliminary results. Eur J Nucl Med Mol Imaging. 2021; 48 (5): 1511-1521. DOI: 10.1007/s00259-020-05088-z
Zagni F, Vichi S, Paolani G et al. A novel tool for predicting the dose distribution of non-sealed 188 Re (Rhenium) resin in non-melanoma skin cancers (NMSC) patients. Med Phys. 2023;50 (7): 4600-4612. DOI: 10.1002/mp.16346. PMID: 36919341
Laliscia C, Coccia N, Fuentes T, Perrone F, Paiar F. Two different sizes of Valencia applicators in non-melanoma skin cancer treatment with iridium-192 high-dose-rate brachytherapy. J Contemp Brachytherapy. 2021; 13 (6): 615-619. DOI: 10.5114/jcb.2021.112111. PMID: 35079246
Stanganelli I, Spagnolo F, Argenziano G, et al, On Behalf Of Italian Melanoma Intergroup Imi. The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts. Cancers (Basel). 2022; 13; 14 (2): 377. DOI: 10.3390/cancers14020377. PMID: 35053539
Tchernev G, Wollina U, Temelkova I. High-Risk Basal Cell Carcinomas of the Head and Neck: Selected Successful Surgical Approach in Three Bulgarian Patients. Open Access Maced J Med Sci. 2019;7 (10): 1665-1668. DOI: 10.3889/oamjms.2019.360. PMID: 31210819
Suppa M, Micantonio T, Di Stefani A et al. Dermoscopic variability of basal cell carcinoma according to clinical type and anatomic location. J Eur Acad Dermatol Venereol. 2015; 29 (9): 1732-41. DOI: 10.1111/jdv.12980. PMID: 25627865
Emiroglu N, Cengiz FP, Kemeriz F. The relation between dermoscopy and histopathology of basal cell carcinoma. An Bras Dermatol. 2015; 90: 351–6. DOI: 10.1590/abd1806-4841.20153446. PMID: 26131865
Lallas A, Apalla Z, Ioannides D, et al. Dermoscopy in the diagnosis and management of basal cell carcinoma. Future Oncol. 2015; 11 (22): 2975-84. DOI: 10.2217/fon.15.193. PMID: 26450622
Navarrete-Dechent C, Cordova M et al. In vivo imaging characterization of basal cell carcinoma and cutaneous response to high-dose ionizing radiation therapy: A prospective study of reflectance confocal microscopy, dermoscopy, and ultrasonography. J Am Acad Dermatol. 2021; 84 (6): 1575-1584 DOI: 10.1016/j.jaad.2020.07.130. PMID: 32827607.22
Krzysztofiak T, Suchorzepka M, Tukiendorf A, Wojcieszek P, Kamińska-Winciorek G. Basal Cell Carcinoma After High Dose Rate Brachytherapy: Medium-term Dermoscopic Evaluation of Cancer's Response. Dermatol Ther (Heidelb). 2023; 13 (9): 2063-2078. DOI: 10.1007/s13555-023-00981-5. PMID: 37558829
Jin H, Yang MY, Kim JM, Kim GW, Kim HS, Ko HC, Kim BS, Kim MB. Arborizing Vessels on Dermoscopy in Various Skin Diseases Other Than Basal Cell Carcinoma. Ann Dermatol. 2017; 29 (3): 288-294. DOI: 10.5021/ad.2017.29.3.288. PMID:28566904
Ghaly M, Zinkin H, Dannenberg M et al. HDR Brachytherapy with Standardized Surface Applicators in the Treatment of Superficial Malignant Skin Lesions. Int J Radiat Oncol Biol Phys 2008; 72: S505-S506. Proceedings of the 50th Annual ASTRO Meeting
Zou Y, Zhu X, Xia R. Reflectance Confocal Microscopy Follow-up of Multifocal Superficial Basal Cell Carcinomas Treated With Imiquimod 5% Cream. Dermatol Pract Concept. 2022; 12 (4): e2022207. DOI: 10.5826/dpc.1204a207. PMID: 36534551
Navarrete-Dechent C, Cordova M et al. In vivo imaging characterization of basal cell carcinoma and cutaneous response to high-dose ionizing radiation therapy: A prospective study of reflectance confocal microscopy, dermoscopy, and ultrasonography. J Am Acad Dermatol. 2021; 84 (6): 1575-1584. DOI: 10.1016/j.jaad.2020.07.130. PMID: 32827607
Eberle FC, Kanyildiz M, Schnabl SM, et al. Three dimensional (3D) histology in daily routine: practical implementation and its evaluation. J Dtsch Dermatol Ges. 2014; 12 (11): 1028-35. doi: 10.1111/ddg.12466. PMID: 25354011
Conforti C, Pizzichetta MA, Vichi S, et al. Sclerodermiform basal cell carcinomas vs. other histotypes: analysis of specific demographic, clinical and dermatoscopic features. J Eur Acad Dermatol Venereol. 2021; 35 (1): 79-87. doi: 10.1111/ddg.12466. PMID: 25354011
van Loo E, Mosterd K, Krekels GA, et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. Eur J Cancer. 2014; 50 (17): 3011-20. DOI: 10.1016/j.ejca.2014.08.018. PMID: 25262378
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Marco Adriano Chessa, Carlotta Baraldi, Francesco Savoia, Lorenzo Maltoni, Giacomo Clarizio, Federica Filippi, Bianca Maria Piraccini, Emi Dika, Annalisa Pitino, Giovanni Tripepi, Federico Zagni, Lidia Strigari, Luigia Vetrone, Stefano Fanti, Paolo Castellucci
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
